



# Biotech Daily

Friday December 2, 2016

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH DOWN: ACTINOGEN UP 9%, ANTEO DOWN 6%**
- \* **GENETIC TECHNOLOGIES PLACEMENT RAISES \$8.1m**
- \* **LBT RAISES \$7m**
- \* **PROTEOMICS RAISES \$1.44m, PLAN FOR \$480k MORE**
- \* **MGC 1st CZECH ORDER FOR \$65k OF CANNABIS SKINCARE COSMETICS**
- \* **FIL TAKES 6% OF SOMNOMED**
- \* **BIO-MELBOURNE APPOINTS LUSIA GUTHRIE INTERIM CEO**
- \* **JUSTYN STEDWELL REPLACES TBG CO SEC BLAIR LUCAS**
- \* **NUHEARA APPOINTS CFO JEAN-MARIE RUDD JOINT CO SEC**

## MARKET REPORT

The Australian stock market fell 1.02 percent on Friday December 2, 2016 with the ASX200 down 56.2 points to 5,444.0 points.

Nine of the Biotech Daily Top 40 stocks were up, 17 fell, 11 traded unchanged and three were untraded. All three Big Caps fell.

Actinogen was the best for the third day in a row, up 0.5 cents or 9.1 percent to six cents with 1.8 million shares traded.

Living Cell climbed 6.7 percent; Airxpanders, Benitec, Cyclopharm, Orthocell and Starpharma were up more than five percent; Mesoblast rose 2.5 percent; with Ellex up 1.9 percent.

Anteo led the falls, down 0.3 cents or 6.25 percent to 4.5 cents with 3.5 million shares traded, followed by Genetic Signatures down 6.1 percent to 46 cents with 170,607 shares traded.

Compumedics and Pro Medicus lost more than five percent; Admedus and Neuren fell more than four percent; Avita, Impedimed, Osprey and Resmed were down more than three percent; Nanosonics, Reva and Sirtex shed more than two percent; Cochlear, CSL, Opthea, Polynovo and Prana were down one percent or more; with Clinuvel and Medical Developments down by less than one percent.

### GENETIC TECHNOLOGIES

Genetic Technologies says it has raised \$8,136,000 in a placement at 1.13 cents a share to US professional and sophisticated investors.

Genetic Technologies said was selling the securities directly to the US investors and had retained the Maxim Group LLC as its placement agent.

The company said the 720,000,000 placement shares were represented by 4,800,000 American depositary shares (ADS) with each ADS equivalent to 150 Australian shares. Genetic Technologies said the funds would be used to support medium-term capital requirements and with existing cash reserves would facilitate expansion requirements for the Brevagenplus breast cancer risk test, the development and commercialization of the colorectal cancer risk assessment test, announced this week, and for general working capital purposes (BD: Nov 29, 2016).

Genetic Technologies chief executive officer Eutillio Buccilli said that the funds would “significantly enhance the company’s long term future and ability to achieve our overall corporate mission to become a leader in the genomics-focused oncology diagnostics industry while enhancing our pipeline of risk-assessment products”.

Genetic Technologies retreated half a cent or 27.8 percent to 1.3 cents with 11.1 million shares traded.

### LBT INNOVATIONS

LBT says it has raised \$7,001,342 in an oversubscribed placement at 31 cents a share to professional and sophisticated investors.

LBT said that the placement shares came with one free attaching option for every two shares subscribed, exercisable at 44.25 cents by December 9, 2018.

The company said that the funds would be used to accelerate the delivery to market of laboratory instruments integrated with its automated plate assessment system (APAS).

LBT said that the sole lead manager for the offer was Bell Potter Securities, with Roth Capital Partners acting as the sole US placement agent.

LBT chief executive Brent Barnes said the placement brought new Australian and US institutional investors to the share register.

The company said that its directors bought shares totalling \$340,000.

“The funds raised will be used to accelerate the delivery to market of APAS Independence and APAS Incubot instruments, which places the company in a stronger position as it relates to establishing global distribution arrangements,” Mr Barnes said.

LBT fell four cents or 10.4 percent to 34.5 cents with 1.9 million shares traded.

### PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics said it has raised \$1,440,000 in an oversubscribed placement at 24 cents a share and hopes to raise a further \$480,000 through a share purchase plan.

Proteomics said that the funds would be used to accelerate commercialization of its, Promarkerd test and the rollout of new analytical testing services for clinical trials.

The company said that that K S Capital was the lead manager to the placement.

Proteomics said that eligible shareholders could subscribe for up to \$15,000 worth of shares at 24 cents a share to raise up to \$480,000, and while directors were not permitted to participate in the placement they would take their full entitlements under the share plan.

The company said that the share plan record date was December 1, the offer would open on December 7 and close on December 21, 2016.

Proteomics fell 2.5 cents or 9.1 percent to 25 cents.

### [MGC \(MEDICAL GRADE CANNABIS\) PHARMACEUTICALS](#)

MGC says it has received its “first major sales order and ... revenues” of \$65,000 of cannabis cosmetics from Czech Republic distributor Czech Medical Herbs SRO. MGC said that Czech Medical would distribute its skin cosmetics to more than 80 retail outlets in the Czech Republic in an agreement worth EUR320,000 (A\$500,000) per year. MGC fell 0.2 cents or 4.3 percent to 4.5 cents with 8.3 million shares traded.

### [SOMNOMED](#)

The Hong Kong and Singapore-based FIL Limited says it has increased its substantial holding in Somnomed from 2,863,471 shares (5.05%) to 3,519,239 shares (6.13%). FIL said it bought the shares between July 20 and November 29, 2016, at prices ranging from \$3.27 to \$3.65. Somnomed was up 10 cents or 2.9 percent to \$3.60.

### [BIO-MELBOURNE NETWORK](#)

The Bio-Melbourne Network says Lusia Guthrie has been appointed interim chief executive officer while Dr Krystal Evans takes parental leave until May 2017. The Network said that Ms Guthrie had 30 years’ experience in the pharmaceutical and medical technology sector and most recently was the co-founder and chief executive officer of LBT Innovations. Ms Guthrie continues as the chair of LBT’s Switzerland-based Clever Culture Systems AG joint-venture with Hettich AG (BD: Oct 10, 2016). The Bio-Melbourne Network said that Ms Guthrie start on January 9, 2017. Biotech Daily wishes Dr Evans all the best for her parental leave.

### [TBG DIAGNOSTICS](#)

TBG says that Justyn Stedwell has been appointed company secretary replacing Blair Lucas, who “resigned due to a change in the strategic direction of his business”. TBG said Mr Stedwell was had 10 years’ experience as a company secretary of ASX companies, including Solagran and Rhinomed (formerly Helicon Group and Conseгна). The company said that Mr Stedwell held a Bachelor of Commerce from Monash University, a Graduate Diploma of Accounting from Deakin University and a Graduate Diploma in Applied Corporate Governance from the Governance Institute of Australia. TBG was untraded at 19.5 cents.

### [NUHEARA](#)

Nuheara says that chief financial officer Jean-Marie Rudd has been appointed as joint company secretary, joining Susan Hunter, effective immediately. Nuheara said Ms Rudd joined the company as chief financial officer in August 2016 and had more than 20 years’ experience in the corporate sector and professional services, with “almost 10 years as chief financial officer and company secretary”. Nuheara was up 0.1 cents or 1.6 percent to 6.5 cents with 2.05 million shares traded.